Literature DB >> 21436685

Application of umbilical cord serum eyedrops for recurrent corneal erosions.

Kyung-Chul Yoon1, Won Choi, In-Cheon You, Jin Choi.   

Abstract

PURPOSE: To investigate the efficacy of umbilical cord serum eyedrops for the treatment of patients with recurrent corneal erosions.
METHODS: Thirty-five eyes of 35 patients with recurrent corneal erosions were studied. Eighteen eyes were treated with 20% umbilical cord serum eyedrops in addition to artificial tears (group A), and 17 eyes received artificial tears only (group B). Frequency of recurrence of corneal erosions was compared between the 2 groups.
RESULTS: The study included 17 male and 18 female patients. Mean age was 46.6 ± 13.4 years, and mean follow-up duration was 14.7 ± 2.5 months. No significant differences in age, sex, and follow-up duration were observed between the 2 groups. In group A, recurrence occurred 2 times in 3 eyes, 1 time in 3 eyes, and did not occur in 12 eyes. In group B, recurrence occurred 5 times in 1 eye, 3 times in 5 eyes, 2 times in 8 eyes, 1 time in 2 eyes, and did not occur in 1 eye. The mean frequency of recurrence was 0.50 ± 0.79 (0.04 ± 0.07 per month) in group A and 2.24 ± 1.09 (0.15 ± 0.08 per month) in group B (P < 0.01). No significant complications associated with serum use were observed.
CONCLUSIONS: In the treatment of recurrent corneal erosions, umbilical cord serum eyedrops may be effective in reducing the number of recurrences.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21436685     DOI: 10.1097/ICO.0b013e31820d850f

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  14 in total

1.  Cord blood serum-based eye drops: the impact of donor haematological and obstetric factors on the variability of epidermal growth factor levels.

Authors:  Piera Versura; Marina Buzzi; Giuseppe Giannaccare; Marco Grillini; Adriana Terzi; Pasqualepaolo Pagliaro; Emilio C Campos
Journal:  Blood Transfus       Date:  2013-10-03       Impact factor: 3.443

2.  Umbilical cord blood serum therapy for the management of persistent corneal epithelial defects.

Authors:  Elif Erdem; Meltem Yagmur; Inan Harbiyeli; Hande Taylan-Sekeroglu; Reha Ersoz
Journal:  Int J Ophthalmol       Date:  2014-10-18       Impact factor: 1.779

3.  Targeting growth factor supply in keratopathy treatment: comparison between maternal peripheral blood and cord blood as sources for the preparation of topical eye drops.

Authors:  Piera Versura; Marina Buzzi; Giuseppe Giannaccare; Adriana Terzi; Michela Fresina; Claudio Velati; Emilio C Campos
Journal:  Blood Transfus       Date:  2015-07-09       Impact factor: 3.443

Review 4.  Interventions for recurrent corneal erosions.

Authors:  Stephanie L Watson; Vannessa Leung
Journal:  Cochrane Database Syst Rev       Date:  2018-07-09

Review 5.  Use of umbilical cord serum in ophthalmology.

Authors:  Kyung Chul Yoon
Journal:  Chonnam Med J       Date:  2014-12-17

Review 6.  Application of Novel Drugs for Corneal Cell Regeneration.

Authors:  Sang Beom Han; Yu-Chi Liu; Karim Mohamed-Noriega; Jodhbir S Mehta
Journal:  J Ophthalmol       Date:  2018-05-02       Impact factor: 1.909

Review 7.  Recurrent corneal erosion: a comprehensive review.

Authors:  Darby D Miller; Syed A Hasan; Nathaniel L Simmons; Michael W Stewart
Journal:  Clin Ophthalmol       Date:  2019-02-11

Review 8.  Blood-Based Treatments for Severe Dry Eye Disease: The Need of a Consensus.

Authors:  Federico Bernabei; Matilde Roda; Marina Buzzi; Marco Pellegrini; Giuseppe Giannaccare; Piera Versura
Journal:  J Clin Med       Date:  2019-09-17       Impact factor: 4.241

9.  Plasma derived from human umbilical cord blood: Potential cell-additive or cell-substitute therapeutic for neurodegenerative diseases.

Authors:  Jared Ehrhart; Paul R Sanberg; Svitlana Garbuzova-Davis
Journal:  J Cell Mol Med       Date:  2018-10-18       Impact factor: 5.310

10.  Effect of epidermal growth factor ointment on persistent epithelial defects of the cornea.

Authors:  Hyun Sik Moon; Lan Li; Hyeon Jeong Yoon; Yong Sok Ji; Kyung Chul Yoon
Journal:  BMC Ophthalmol       Date:  2020-04-15       Impact factor: 2.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.